Why Leptomeningeal Metastasis Matters Now
With the widespread use of targeted therapies and novel agents, survival times for patients with advanced lung cancer have increased significantly. Most people are familiar with “brain metastasis,” which usually refers to lesions within the brain parenchyma itself. However, as lung cancer treatment continues to improve and patient survival extends, the detection rate of leptomeningeal metastasis (LM) is rising steadily.
In simple terms, LM occurs when tumor cells spread into the leptomeninges — the thin membranes that envelop the brain and spinal cord — and into the subarachnoid space. Some patients have no visible brain parenchymal lesions, yet large numbers of tumor cells can be found in their cerebrospinal fluid (CSF). These cells attach and cluster across the entire surface of the spinal cord, triggering a cascade of neurological symptoms.
Symptoms Can Be Subtle but the Impact Is Severe
The symptoms of leptomeningeal metastasis are relatively insidious and easy to miss during routine evaluation. The main presentations include:
- Elevated intracranial pressure: Persistent nausea, headache, and vomiting.
- Neurological symptoms: Highly variable depending on which nerves are affected.
- Cranial nerve involvement: May cause difficulty swallowing, blurred vision, facial weakness or double vision.
- Cauda equina / spinal nerve involvement: Can lead to urinary and fecal incontinence, lower limb numbness or weakness.
Why Routine Imaging Often Misses It
This is where diagnosis becomes challenging. Conventional CT and enhanced MRI scans sometimes fail to clearly display meningeal abnormalities. Many patients require specialized MRI sequences — such as the black-blood sequence — before signs of meningeal involvement become visible.
Case Study: Lung Adenocarcinoma with Leptomeningeal Metastasis
Patient Timeline
| November 2025 | Patient admitted with sudden consciousness disturbance. Initial CT scan showed no acute hemorrhage, cerebral infarction or obvious space-occupying lesion. |
| Lumbar puncture | CSF pressure measured at 300 mmH2O (reference range approximately 80–180). Cytological examination detected malignant cells consistent with leptomeningeal metastasis. Patient had reported headache, nausea and vomiting prior to admission; condition progressed to altered consciousness. |
| January 2026 | Follow-up examination: symptoms markedly improved. CSF pressure and protein levels returned to normal range. Repeat cytology showed no detectable cancer cells. Black-blood MRI demonstrated that previously noted abnormal enhancement signals along the sulci and gyri had resolved, indicating radiological improvement of meningeal disease burden. |
The LM-MDT Multidisciplinary Team Approach
To address the industry-wide diagnostic and therapeutic challenges of lung cancer with leptomeningeal metastasis, our hospital established a dedicated LM-MDT (Leptomeningeal Metastasis Multidisciplinary Team). This team integrates expertise across imaging, laboratory medicine, medical oncology, ultrasound and other specialties to create a seamless diagnostic-to-treatment pathway.
Our comprehensive system includes:
- Black-blood sequence MRI for precise radiological diagnosis
- Standardized cerebrospinal fluid sample collection and analysis protocols
- Neurological function assessment with standardized scoring tools
- Structured intrathecal drug administration workflows
- Ongoing exploratory clinical research aimed at establishing unified diagnostic and treatment standards
We remain committed to advancing both academic understanding and clinical practice in this field, providing standardized, full-cycle comprehensive care for patients with advanced lung cancer and central nervous system metastases through an integrated multidisciplinary model.
About the Expert
Dr. Li Shuang (李熱)
Vice President of Education & Research, Director of Thoracic Oncology
Shanghai GOBROAD Cancer Hospital
Clinic hours: Tuesday afternoon, Thursday morning
Specialization: Comprehensive treatment and full-cycle management of malignant tumors, focusing on the integrated application of chemotherapy, targeted therapy, immunotherapy and radiotherapy — particularly in neoadjuvant and adjuvant settings.
Professional Affiliations
- Member, Anti-Tumor Drug Safety Management Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Brain Metastoma Study Group, Neuro-Oncology Professional Committee, China Anti-Cancer Association (CACA)
- Member, Chinese Radiotherapy Collaboration Group (CRTOG)
- Member, Cancer Rehabilitation & Palliative Care Professional Committee, Shanghai Anti-Cancer Association